

# Emanuele Angelucci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5512291/publications.pdf>

Version: 2024-02-01

250  
papers

13,346  
citations

18465

62  
h-index

27389

106  
g-index

256  
all docs

256  
docs citations

256  
times ranked

11925  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. <i>New England Journal of Medicine</i> , 2013, 368, 22-33.	13.9	664
2	Bone Marrow Transplantation in Patients with Thalassemia. <i>New England Journal of Medicine</i> , 1990, 322, 417-421.	13.9	580
3	Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia Major. <i>New England Journal of Medicine</i> , 2000, 343, 327-331.	13.9	524
4	Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. <i>Haematologica</i> , 2014, 99, 811-820.	1.7	302
5	Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. <i>Blood</i> , 2002, 100, 17-21.	0.6	278
6	Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00. <i>Journal of Clinical Oncology</i> , 2010, 28, 3644-3652.	0.8	250
7	Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. <i>Blood</i> , 2010, 115, 2755-2762.	0.6	242
8	Marrow Transplantation in Patients with Thalassemia Responsive to Iron Chelation Therapy. <i>New England Journal of Medicine</i> , 1993, 329, 840-844.	13.9	211
9	Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. <i>Blood</i> , 2013, 122, 1072-1078.	0.6	210
10	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 3627-3637.	0.8	204
11	Marrow transplantation for patients with thalassemia: results in class 3 patients. <i>Blood</i> , 1996, 87, 2082-2088.	0.6	202
12	Prophylaxis and treatment of hepatitis B in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2007, 39, 397-408.	0.4	197
13	The MLL recombinome of acute leukemias. <i>Leukemia</i> , 2006, 20, 777-784.	3.3	196
14	New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. <i>Blood</i> , 2004, 104, 1201-1203.	0.6	182
15	Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. <i>Haematologica</i> , 2008, 93, 741-752.	1.7	182
16	Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2000, 25, 401-404.	1.3	177
17	Bone Marrow Transplantation in Adult Thalassemic Patients. <i>Blood</i> , 1999, 93, 1164-1167.	0.6	169
18	ABVD Versus Modified Stanford V Versus MOPPEBVCAD With Optional and Limited Radiotherapy in Intermediate- and Advanced-Stage Hodgkin's Lymphoma: Final Results of a Multicenter Randomized Trial by the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2005, 23, 9198-9207.	0.8	167

#	ARTICLE	IF	CITATIONS
19	The cure of thalassemia by bone marrow transplantation. <i>Blood Reviews</i> , 2002, 16, 81-85.	2.8	166
20	Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. <i>Blood</i> , 2014, 123, 2333-2342.	0.6	162
21	Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000â€”2010. <i>Bone Marrow Transplantation</i> , 2016, 51, 536-541.	1.3	159
22	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv279.	3.0	152
23	Phlebotomy to Reduce Iron Overload in Patients Cured of Thalassemia by Bone Marrow Transplantation. <i>Blood</i> , 1997, 90, 994-998.	0.6	148
24	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	9.4	147
25	Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. <i>Haematologica</i> , 2010, 95, 476-484.	1.7	144
26	Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia) [see comments]. <i>Blood</i> , 1993, 82, 374-377.	0.6	129
27	Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. <i>Haematologica</i> , 2007, 92, 612-618.	1.7	128
28	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 1223-1233.	0.8	127
29	Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. <i>British Journal of Haematology</i> , 1995, 89, 757-761.	1.2	125
30	Marrow Transplantation in Patients with Advanced Thalassemia. <i>New England Journal of Medicine</i> , 1987, 316, 1050-1055.	13.9	123
31	Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. <i>Haematologica</i> , 2008, 93, 1385-1388.	1.7	122
32	The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with Î²-thalassemia major. <i>Blood</i> , 2000, 96, 3624-3629.	0.6	121
33	MARROW TRANSPLANTATION FOR THALASSAEMIA FOLLOWING BUSULPHAN AND CYCLOPHOSPHAMIDE. <i>Lancet</i> , The, 1985, 325, 1355-1357.	6.3	119
34	Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants. <i>Bone Marrow Transplantation</i> , 2000, 25, 815-821.	1.3	115
35	Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. <i>Leukemia Research</i> , 2010, 34, 1576-1588.	0.4	112
36	Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood.. <i>Journal of Clinical Oncology</i> , 1997, 15, 566-573.	0.8	110

#	ARTICLE	IF	CITATIONS
37	Bone Marrow Transplantation in Thalassemia: The Experience of Pesaro. <i>Annals of the New York Academy of Sciences</i> , 1998, 850, 270-275.	1.8	108
38	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 689-696.	0.8	107
39	Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2009, 15, 5002-5007.	3.2	103
40	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. <i>Clinical Infectious Diseases</i> , 2017, 65, 1884-1896.	2.9	103
41	Consensus-based definition of unfit to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. <i>Leukemia</i> , 2013, 27, 997-999.	3.3	101
42	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2017, 18, 1076-1088.	5.1	100
43	Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2007, 39, 89-99.	1.3	95
44	Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (<sc>GIMEMA MDS</sc>0306 <sc>T</sc>rial). <i>European Journal of Haematology</i> , 2014, 92, 527-536.	1.1	90
45	Fate of iron stores in thalassaemia after bone-marrow transplantation. <i>Lancet</i> , The, 1993, 342, 1388-1391.	6.3	89
46	Reversibility of Cirrhosis in Patients Cured of Thalassemia by Bone Marrow Transplantation. <i>Annals of Internal Medicine</i> , 2002, 136, 667.	2.0	89
47	Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. <i>Haematologica</i> , 2014, 99, 788-793.	1.7	85
48	Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. <i>Haematologica</i> , 2008, 93, 951-952.	1.7	82
49	Hematopoietic Stem Cell Transplantation in Thalassemia. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 456-462.	0.9	79
50	Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. <i>Blood</i> , 2010, 116, 2875-2883.	0.6	79
51	Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1â€“Risk Myelodysplastic Syndromes. <i>Annals of Internal Medicine</i> , 2020, 172, 513.	2.0	78
52	Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1983-1987.	2.0	77
53	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. <i>Lancet Oncology</i> , The, 2015, 16, 1506-1514.	5.1	76
54	Limitations of Magnetic Resonance Imaging in Measurement of Hepatic Iron. <i>Blood</i> , 1997, 90, 4736-4742.	0.6	73

#	ARTICLE	IF	CITATIONS
55	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	0.6	72
56	VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (ILL) study. <i>Annals of Oncology</i> , 2004, 15, 123-128.	0.6	71
57	Trichosporon beigeli: a life-threatening pathogen in immunocompromised hosts. <i>Bone Marrow Transplantation</i> , 2000, 25, 745-749.	1.3	70
58	GRAFT-VERSUS-HOST DISEASE AFTER BONE MARROW TRANSPLANTATION FOR THALASSEMIA. <i>Transplantation</i> , 1997, 63, 854-860.	0.5	70
59	Halting pro-survival autophagy by TGF $\beta$ 2 inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients. <i>Leukemia</i> , 2016, 30, 640-648.	3.3	69
60	Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2167-2171.	2.0	69
61	Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2341-2346.	1.3	69
62	New Strategies in the Treatment of the Thalassemias. <i>Annual Review of Medicine</i> , 2005, 56, 157-171.	5.0	68
63	Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. <i>Journal of Hematology and Oncology</i> , 2020, 13, 46.	6.9	68
64	Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 552-561.	2.0	66
65	Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. <i>Haematologica</i> , 2009, 94, 1250-1258.	1.7	65
66	Bone marrow transplantation in adult thalassemia. <i>Blood</i> , 1992, 80, 1603-1607.	0.6	64
67	Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Haematologica</i> , 2010, 95, 983-988.	1.7	64
68	The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. <i>Blood</i> , 2000, 96, 3624-9.	0.6	64
69	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 581-588.	2.0	61
70	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e401-e419.	0.2	61
71	Bone Marrow Transplantation in Thalassemia. <i>Hematology/Oncology Clinics of North America</i> , 1991, 5, 549-556.	0.9	59
72	Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade $\frac{1}{2}$ , ICL670). <i>European Journal of Haematology</i> , 2007, 78, 540-542.	1.1	59

#	ARTICLE	IF	CITATIONS
73	Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia. <i>British Journal of Haematology</i> , 1995, 89, 868-873.	1.2	59
74	Allogeneic stem cell transplantation for thalassemia major. <i>Haematologica</i> , 2008, 93, 1780-1784.	1.7	59
75	Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2015, 168, 361-370.	1.2	59
76	A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. <i>Leukemia</i> , 2018, 32, 413-418.	3.3	58
77	Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. <i>Leukemia</i> , 2014, 28, 642-648.	3.3	57
78	Evaluation of cardiac status in iron-loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. <i>British Journal of Haematology</i> , 1998, 103, 916-921.	1.2	56
79	HIF-1 $\alpha$ of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target. <i>Clinical Cancer Research</i> , 2014, 20, 847-858.	3.2	54
80	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. <i>Human Molecular Genetics</i> , 2016, 25, 1663-1676.	1.4	52
81	A storm in the niche: Iron, oxidative stress and haemopoiesis. <i>Blood Reviews</i> , 2018, 32, 29-35.	2.8	52
82	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. <i>Leukemia</i> , 2017, 31, 2449-2457.	3.3	51
83	Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Journal of Hematology and Oncology</i> , 2021, 14, 53.	6.9	51
84	Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. <i>Bone Marrow Transplantation</i> , 1997, 20, 915-920.	1.3	50
85	A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1243-1249.	2.0	49
86	Marrow transplantation for patients with thalassemia: results in class 3 patients. <i>Blood</i> , 1996, 87, 2082-8.	0.6	46
87	The role of oxidant injury in the pathophysiology of human thalassemsias. <i>Redox Report</i> , 2003, 8, 241-245.	1.4	45
88	Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the <i>Fondazione Italiana Linfomi</i> . <i>Haematologica</i> , 2018, 103, 1345-1350.	1.7	45
89	Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2008, 26, 98-103.	0.8	44
90	Bone marrow transplantation in adult thalassemic patients. <i>Blood</i> , 1999, 93, 1164-7.	0.6	44

#	ARTICLE	IF	CITATIONS
91	The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with $\beta^2$ -thalassemia major. <i>Blood</i> , 2000, 96, 3624-3629.	0.6	43
92	Bone marrow transplantation in thalassemia: modifications of hepatic iron overload and associated lesions after long-term engrafting. <i>Liver</i> , 2008, 14, 14-24.	0.1	42
93	Pre-Engraftment Bloodstream Infections after Allogeneic Hematopoietic Cell Transplantation: Impact of T Cell-Replete Transplantation from a Haploidentical Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 109-118.	2.0	41
94	Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepea, busulfan, and fludarabine. <i>Journal of Hematology and Oncology</i> , 2018, 11, 110.	6.9	41
95	Sudden cardiac tamponade after chemotherapy for marrow transplantation in thalassaemia. <i>Lancet</i> , The, 1992, 339, 287-289.	6.3	40
96	Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine. <i>Leukemia</i> , 2011, 25, 1910-1913.	3.3	40
97	High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. <i>Haematologica</i> , 2013, 98, 1718-1725.	1.7	40
98	Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1313-1321.	2.0	40
99	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2021, 96, 69-79.	2.0	40
100	Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major. <i>Annals of the New York Academy of Sciences</i> , 2016, 1368, 115-121.	1.8	39
101	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. <i>Blood Advances</i> , 2020, 4, 2073-2083.	2.5	39
102	Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. <i>Annals of Oncology</i> , 2014, 25, 447-454.	0.6	38
103	Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 119-126.	2.0	37
104	$\alpha$ -Interferon treatment of chronic hepatitis C after bone marrow transplantation for homozygous $\beta^2$ -thalassemia. <i>Bone Marrow Transplantation</i> , 1997, 20, 767-772.	1.3	36
105	Treatment of Iron Overload in the "Ex-Thalassemic": Report from the Phlebotomy Programa. <i>Annals of the New York Academy of Sciences</i> , 1998, 850, 288-293.	1.8	36
106	De-Escalation and Discontinuation of Empirical Antibiotic Treatment in a Cohort of Allogeneic Hematopoietic Stem Cell Transplantation Recipients during the Pre-Engraftment Period. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1721-1726.	2.0	36
107	Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients. <i>Journal of Pathology</i> , 2013, 229, 87-98.	2.1	34
108	Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2021, 35, 215-224.	3.3	34



#	ARTICLE	IF	CITATIONS
109	Anemia in -thalassemia patients targets hepatic hepcidin transcript levels independently of iron metabolism genes controlling hepcidin expression. <i>Haematologica</i> , 2008, 93, 111-115.	1.7	33
110	Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. <i>Leukemia Research</i> , 2015, 39, 957-963.	0.4	32
111	High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. <i>Haematologica</i> , 2005, 90, 793-801.	1.7	31
112	Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. <i>Blood Advances</i> , 2020, 4, 3900-3912.	2.5	30
113	Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2766-2775.	3.3	30
114	Second marrow transplants for graft failure in patients with thalassemia. <i>Bone Marrow Transplantation</i> , 1999, 24, 1299-1306.	1.3	29
115	Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival. <i>Haematologica</i> , 2016, 101, e245-e248.	1.7	29
116	Reduced intensity <sc>VEPEMB</sc> regimen compared with standard <sc>ABVD</sc> in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (<sc>FIL</sc>). <i>British Journal of Haematology</i> , 2016, 172, 879-888.	1.2	29
117	Risk of malignant lymphoma following viral hepatitis infection. <i>International Journal of Hematology</i> , 2008, 87, 474-483.	0.7	28
118	Reduced Left Ventricular Contractile Reserve Identified by Low Dose Dobutamine Echocardiography as an Early Marker of Cardiac Involvement in Asymptomatic Patients with Thalassemia Major. <i>Echocardiography</i> , 1996, 13, 463-472.	0.3	27
119	Transplantation in thalassemia: Revisiting the Pesaro risk factors 25 years later. <i>American Journal of Hematology</i> , 2017, 92, 411-413.	2.0	27
120	HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 114-120.	2.0	27
121	Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2021, 14, 84.	6.9	27
122	Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. <i>American Journal of Hematology</i> , 2012, 87, 1047-1051.	2.0	26
123	Intravenous chelation therapy during transplantation for thalassemia. <i>Haematologica</i> , 1995, 80, 300-4.	1.7	26
124	Kaposi's sarcoma after allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1997, 19, 629-631.	1.3	25
125	CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease. <i>Haematologica</i> , 2012, 97, 568-571.	1.7	25
126	Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes. <i>Leukemia Research</i> , 2017, 62, 108-115.	0.4	25



#	ARTICLE	IF	CITATIONS
127	Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 27-35.	2.0	25
128	Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 843-851.	3.2	25
129	Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. <i>Annals of Oncology</i> , 2005, 16, 228-233.	0.6	24
130	Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. <i>British Journal of Haematology</i> , 2017, 177, 741-750.	1.2	23
131	Bone marrow transplantation in thalassemia. <i>Cancer Treatment and Research</i> , 1997, 77, 305-315.	0.2	23
132	Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. <i>American Journal of Hematology</i> , 2008, 83, 717-720.	2.0	22
133	Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. <i>Cancer</i> , 2018, 124, 2228-2237.	2.0	22
134	Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients. <i>Bone Marrow Transplantation</i> , 2019, 54, 708-712.	1.3	22
135	Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case Report. <i>Drugs in R and D</i> , 2014, 14, 9-11.	1.1	21
136	Treatment of hepatitis C in patients with thalassemia. <i>Haematologica</i> , 2008, 93, 1121-1123.	1.7	20
137	Haploidentical bone marrow transplantation from mother to child with advanced leukemia. <i>Bone Marrow Transplantation</i> , 1995, 16, 529-35.	1.3	20
138	Bone marrow transplantation for transfused patients with severe aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning therapy: long-term follow-up from a single center. <i>Bone Marrow Transplantation</i> , 1999, 24, 253-257.	1.3	19
139	Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome "Emphasis on optimized dosing schedules and new formulations. <i>Leukemia Research</i> , 2015, 39, 1028-1033.	0.4	19
140	Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 698-703.	2.0	19
141	The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. <i>Annals of Hematology</i> , 2016, 95, 211-219.	0.8	18
142	Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies. <i>Value in Health</i> , 2019, 22, 1303-1310.	0.1	18
143	Use of <i>Aspergillus fumigatus</i> real-time PCR in bronchoalveolar lavage samples (BAL) for diagnosis of invasive aspergillosis, including azole-resistant cases, in high risk haematology patients: the need for a combined use with galactomannan. <i>Medical Mycology</i> , 2019, 57, 987-996.	0.3	18
144	Pubertal development in thalassaemic patients after allogeneic bone marrow transplantation. <i>European Journal of Pediatrics</i> , 1993, 152, 993-997.	1.3	17

#	ARTICLE	IF	CITATIONS
145	Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2015, 39, 859-865.	0.4	17
146	Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2501-2508.	2.0	17
147	Hepatitis C virus infection in thalassemia patients undergoing allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1994, 14, 369-72.	1.3	17
148	Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results. <i>Bone Marrow Transplantation</i> , 2002, 29, 1-8.	1.3	16
149	Dramatic erythroid response to low-dose thalidomide in two patients with transfusion independent thalassemia and severe post-transfusional alloimmune hemolysis. <i>American Journal of Hematology</i> , 2015, 90, E141.	2.0	16
150	Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy. <i>BMJ Supportive and Palliative Care</i> , 2016, 6, 80-88.	0.8	16
151	An unusual marrow transplant complication: cardiac myxoma. <i>Bone Marrow Transplantation</i> , 1998, 21, 825-827.	1.3	15
152	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	1.1	15
153	Non-transferrin-bound iron and oxidative stress during allogeneic hemopoietic stem cell transplantation in patients with or without iron overload. <i>American Journal of Hematology</i> , 2018, 93, E250-E252.	2.0	15
154	Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. <i>Bone Marrow Transplantation</i> , 2007, 39, 189-191.	1.3	14
155	Visceral leishmaniasis in hematopoietic cell transplantation: Case report and review of the literature. <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 990-994.	0.8	14
156	Impact of total body irradiation vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1200-1208.	2.0	14
157	A three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2001, 27, 45-51.	1.3	13
158	MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017021.	0.5	13
159	Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major. <i>Annals of Hematology</i> , 2022, 101, 655-665.	0.8	13
160	Antibodies to hepatitis C virus in thalassemia. <i>Haematologica</i> , 1994, 79, 353-5.	1.7	13
161	Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab. <i>Infection</i> , 2019, 47, 59-65.	2.3	12
162	Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies. <i>Quality of Life Research</i> , 2020, 29, 815-823.	1.5	12

#	ARTICLE	IF	CITATIONS
163	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018, 59, 2904-2910.	0.6	11
164	Enhanced macrophagic attack on beta-thalassemia major erythroid precursors. <i>Haematologica</i> , 2002, 87, 578-83.	1.7	11
165	Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide+dexamethasone incorporated into double autologous transplantation. <i>Annals of Hematology</i> , 2013, 92, 1271-1280.	0.8	10
166	Complication free survival long-term after hemopoietic cell transplantation in thalassemia. <i>Haematologica</i> , 2018, 103, 1094-1096.	1.7	10
167	Guest Editor: Raffaella Origa IRON TOXICITY AND HEMOPOIETIC CELL TRANSPLANTATION: TIME TO CHANGE THE PARADIGM.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019030.	0.5	10
168	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2194-2202.	1.3	10
169	Radiomics and Artificial Intelligence for Outcome Prediction in Multiple Myeloma Patients Undergoing Autologous Transplantation: A Feasibility Study with CT Data. <i>Diagnostics</i> , 2021, 11, 1759.	1.3	10
170	<i>Aspergillus</i> PCR in bronchoalveolar lavage diagnostic accuracy for invasive pulmonary aspergillosis in critically ill patients. <i>Mycoses</i> , 2022, 65, 411-418.	1.8	10
171	Bone marrow transplantation for thalassemia. <i>Indian Journal of Pediatrics</i> , 1993, 60, 517-523.	0.3	9
172	High prevalence of non-HFE gene-associated haemochromatosis in patients from southern Italy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 17-24.	1.4	9
173	Risk of lymphoma subtypes and dietary habits in a Mediterranean area. <i>Cancer Epidemiology</i> , 2015, 39, 1093-1098.	0.8	9
174	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 622-634.	1.3	9
175	Hematopoietic Cell Transplantation in Thalassemia and Sickle Cell Disease: Report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry: 2000-2017. <i>Blood</i> , 2018, 132, 168-168.	0.6	9
176	Reproducibility of liver iron concentration measured on a biopsy sample: A validation study in vivo. <i>American Journal of Hematology</i> , 2015, 90, 87-90.	2.0	8
177	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1357-1366.	1.2	8
178	Thiotepa+busulfan+fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1593-1602.	1.3	8
179	Outcome of replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2021, 127, 2507-2514.	2.0	8
180	ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. <i>Annals of Oncology</i> , 2008, 19, 763-768.	0.6	7

#	ARTICLE	IF	CITATIONS
181	Risk of HBV liver disease in isolated antiHbc patients receiving immuno-chemotherapy for non Hodgkin lymphoma. <i>Haematologica</i> , 2008, 93, e66-e66.	1.7	7
182	Sinusal bradycardia after receiving intermediate or high dose cytarabine: four cases from a single institution. <i>European Journal of Cancer Care</i> , 2009, 18, 320-321.	0.7	7
183	The evolving clinical scenario of myelodysplastic syndrome: The need for a complete and up to date upfront diagnostic assessment. <i>European Journal of Internal Medicine</i> , 2010, 21, 490-495.	1.0	7
184	B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2016, 57, 2375-2381.	0.6	7
185	Myeloablative Unrelated Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2438-2446.	2.0	7
186	Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1944-1952.	1.3	7
187	Reversal features of hepatic hemosiderosis and haemochromatosis in thalassemia after bone marrow transplantation. <i>Progress in Clinical and Biological Research</i> , 1989, 309, 299-314.	0.2	7
188	Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide. <i>Bone Marrow Transplantation</i> , 1994, 13, 197-201.	1.3	7
189	A COMPARATIVE TRIAL OF POSTTRANSPLANT IMMUNOSUPPRESSION IN PATIENTS TRANSPLANTED FOR THALASSEMIA. <i>Transplantation</i> , 1988, 45, 566-569.	0.5	6
190	Sensorimotor peripheral neuropathy in an elderly AML patient in complete remission while receiving gemtuzumab ozogamicin as maintenance therapy. <i>Annals of Hematology</i> , 2006, 85, 411-412.	0.8	6
191	Safety of hematopoietic stem cell donation in glucose 6 phosphate dehydrogenase-deficient donors. <i>Bone Marrow Transplantation</i> , 2013, 48, 36-39.	1.3	6
192	Hurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia. <i>Stem Cells Translational Medicine</i> , 2022, 11, 407-414.	1.6	6
193	Glucose-6-Phosphate Dehydrogenase Polymorphism and Lymphoma Risk. <i>Tumori</i> , 2007, 93, 121-123.	0.6	5
194	Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study. <i>Hematological Oncology</i> , 2016, 34, 17-21.	0.8	5
195	Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. <i>Leukemia and Lymphoma</i> , 2016, 57, 2370-2374.	0.6	5
196	Estimates of Environmental Exposure to Radiofrequency Electromagnetic Fields and Risk of Lymphoma Subtypes. <i>Radiation Research</i> , 2018, 189, 541-547.	0.7	5
197	Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants. <i>Bone Marrow Transplantation</i> , 2018, 53, 1560-1567.	1.3	5
198	Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis. <i>Cancer Medicine</i> , 2019, 8, 7567-7576.	1.3	5

#	ARTICLE	IF	CITATIONS
199	ALSF position paper on HCV in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2019, 51, 10-23.	0.4	5
200	Effect of the Thiotepea Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 296-304.	0.2	5
201	Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study. <i>Annals of Hematology</i> , 2012, 91, 527-532.	0.8	4
202	A genome-wide association study by ImmunoChip reveals potential modifiers in myelodysplastic syndromes. <i>Experimental Hematology</i> , 2016, 44, 1034-1038.	0.2	4
203	Sudden cardiac failure in a $\beta^2$ -thalassemia major patient receiving chemotherapy for acute promyelocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 628-629.	0.6	3
204	Iron overload, cardiac iron loading and function in myelodysplastic syndrome. <i>Leukemia Research</i> , 2009, 33, 743-744.	0.4	3
205	Household contact with pets and birds and risk of lymphoma. <i>Cancer Causes and Control</i> , 2011, 22, 159-165.	0.8	3
206	Ibrutinib: another weapon in our arsenal against lympho-proliferative disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2715-2718.	0.9	3
207	Another Step Forward in Iron Chelation Therapy. <i>Acta Haematologica</i> , 2015, 134, 231-232.	0.7	3
208	Acetyltransferase polymorphisms are associated with risk of lymphoma subtypes. <i>Hematological Oncology</i> , 2016, 34, 79-83.	0.8	3
209	Haploidentical bone marrow transplantation in patients with advanced myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2017, 92, E117-E119.	2.0	3
210	Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-Risk Myelodysplastic Syndromes. <i>Annals of Internal Medicine</i> , 2020, 173, 595-596.	2.0	3
211	Hematopoietic Stem Cell Transplantation in Thalassemia and Related Disorders. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2009, 1, e2009015.	0.5	3
212	Iron-mediated tissue damage in acquired ineffective erythropoiesis disease: It's more a matter of burden or more of exposure to toxic iron form?. <i>Leukemia Research</i> , 2022, 114, 106792.	0.4	3
213	A New Approach to Bone Marrow Transplantation in Thalassemia. <i>Annals of the New York Academy of Sciences</i> , 1990, 612, 394-397.	1.8	2
214	Successful Treatment of Severe Thalassemia. <i>New England Journal of Medicine</i> , 1999, 341, 92-92.	13.9	2
215	Unexpected CNS localization in M2 acute myeloid leukemia: A link with past heroin addiction?. <i>American Journal of Hematology</i> , 2008, 83, 682-683.	2.0	2
216	Cardiogenic Shock during First Infusion of Anthracycline Chemotherapy in a Patient with Hodgkin Lymphoma: An Unusual Event. <i>Cardiology</i> , 2018, 139, 7-10.	0.6	2

#	ARTICLE	IF	CITATIONS
217	High versus low dose cyclosporineâ€A, after allogeneic marrow transplantation in leukemia: Longâ€term followâ€up of a randomized study. American Journal of Hematology, 2018, 93, E185.	2.0	2
218	Iron Chelation Therapy in MDS â€“ The Final Answer. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S75-S76.	0.2	2
219	Advances in transplantation and gene therapy in transfusion-dependent $\beta^2$ -thalassemia. Advances in Cell and Gene Therapy, 2019, 2, e25.	0.6	2
220	Can any new thalassemia therapy achieve a better than 97.4% cure rate?. American Journal of Hematology, 2020, 95, 1233-1234.	2.0	2
221	Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. Cancer, 2021, 127, 2015-2024.	2.0	2
222	Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results. , 0, .		2
223	Selecting $\beta^2$ -Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm. Blood, 2019, 134, 972-972.	0.6	2
224	Italian Society of Hematology guidelines for thalassemia and non-invasive iron measurements: author reply. Haematologica, 2009, 94, 295-296.	1.7	2
225	Pancreatic beta-Cell Function Before and After Bone Marrow Transplantation for Thalassemia. , 1995, , 69-72.		2
226	Marrow Transplantation for Children with Acute Leukemia: Experience of Pesaro. Acta Haematologica, 1989, 82, 7-11.	0.7	1
227	Regression of multiple hepatic masses in a young patient with thalassaemia. Pediatric Radiology, 2000, 30, 161-164.	1.1	1
228	Management of Transfusional Chronic Iron Overload: Focus on Deferasirox. Clinical Medicine Therapeutics, 2009, 1, CMT.S1970.	0.1	1
229	Long term outcome of localized aggressive non-Hodgkin lymphoma treated with a short weekly chemotherapy regimen (doxorubicin, cyclophosphamide, bleomycin, vincristine, and prednisone) and involved field radiotherapy: result of a Gruppo Italiano Multiregionale per lo Studio dei Linfomi e Leucemie (GIMURELL) study. Leukemia and Lymphoma, 2009, 50, 1475-1481.	0.6	1
230	Patient Satisfaction With Nursing Staff in Bone Marrow Transplantation and Hematology Units. Transplantation Proceedings, 2010, 42, 2257-2263.	0.3	1
231	Should every patient with MDS get iron chelation â€“ probably yes.. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017055.	0.5	1
232	Biosimilars G-CSF versus originator G-CSF in post allotransplant recovery. A case-control study. American Journal of Hematology, 2016, 91, E7-E8.	2.0	1
233	A new medical therapy for anemia in thalassemia. Blood, 2019, 133, 1267-1268.	0.6	1
234	Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusionâ€dependent patients with myelodysplastic syndromes. European Journal of Haematology, 2019, 102, 442-443.	1.1	1



#	ARTICLE	IF	CITATIONS
235	Phlebotomy to Reduce Iron Overload in Patients Cured of Thalassemia by Bone Marrow Transplantation. <i>Blood</i> , 1997, 90, 994-998.	0.6	1
236	Limitations of Magnetic Resonance Imaging in Measurement of Hepatic Iron. <i>Blood</i> , 1997, 90, 4736-4742.	0.6	1
237	HLA-mismatched bone marrow transplantation in thalassemia. <i>Bone Marrow Transplantation</i> , 1993, 12 Suppl 1, 67-9.	1.3	1
238	Stem Cell Transplantation. , 2009, , 774-790.		0
239	Bone Marrow Transplantation in Leukemia: Experience of Pesaro. <i>Acta Haematologica</i> , 1987, 78, 187-189.	0.7	0
240	Marginal zone B-cell lymphoma arising in donor cells in a Hepatitis-C virus infected patient over 20 years after allogeneic bone marrow transplantation. <i>Leukemia and Lymphoma</i> , 2008, 49, 2219-2221.	0.6	0
241	A case of fatal overwhelming microgranular variant (M3v) of acute promyelocytic leukemia with extensive extramedullary involvement. <i>International Journal of Hematology</i> , 2010, 91, 551-552.	0.7	0
242	Do matrix metalloproteinase-1 and glucose-6-phosphate dehydrogenase gene polymorphisms interact in promoting lymphoma development?. <i>Leukemia and Lymphoma</i> , 2013, 54, 2734-2735.	0.6	0
243	Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation. <i>Blood Research</i> , 2019, 54, 288-290.	0.5	0
244	Unintentional human leukocyte antigen mismatched haematopoietic cell transplant: clinical course and root cause analysis. <i>British Journal of Haematology</i> , 2020, 191, e35-e37.	1.2	0
245	A large cooperative biological and clinical study to better understand and improve treatment of the rare t(8;16)(p11;p13) acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 192, 800-802.	1.2	0
246	Bone Marrow Transplantation for Thalassemia: 156 Cases Transplanted in Pesaro. <i>Plant Systematics and Evolution Supplementum = Entwicklungsgeschichte Und Systematik Der Pflanzen Supplementum</i> , 1988, , 187-188.	1.5	0
247	New approach to bone marrow transplantation in thalassemia. , 1991, , 425-428.		0
248	Bone Marrow Transplantation in Adult Thalassemic Patients. <i>Blood</i> , 1999, 93, 1164-1167.	0.6	0
249	Iron Overload. , 2019, , 353-356.		0
250	Current and Future Therapies for $\beta^2$ -Thalassaemia: A Review Article. <i>European Medical Journal Hematology</i> , 0, , 94-104.	0.0	0